Supernus, Indivior Merger Creates $2.2 Bln CNS Company; Shares Surge In Pre-market
Supernus Pharmaceuticals (SUPN) agreed to merge with Indivior Pharmaceuticals (INDV) in an all-stock deal. The combined CNS biopharma is expected to have about $2.2B in annual revenue, $125M annual cost synergies, and close in Q4 2026. Each SUPN share gets 1.5401 INDV shares, with a $1B special cash dividend to INDV holders. Pre-market, SUPN and INDV rose.
How this was made
The 30-second read
Why it matters
The deal introduces a new combined entity plan (name and Nasdaq listing under SUPN), a defined exchange ratio, a $1 billion special cash dividend for Indivior holders, and a stated synergy target, all of which can drive immediate repricing and merger-arbitrage positioning.
Market read
Definitive M&A terms with a special dividend and a planned post-merger Nasdaq listing can materially affect both stocks’ valuation and deal-completion probability.
What to watch
Merger-arb outcomes will hinge on regulatory review, financing of the $1 billion special dividend mechanics, and whether the $125 million synergy target is achievable on the stated timeline.
Background
Supernus and Indivior announced a definitive all-stock merger agreement to form a combined CNS biopharmaceutical company.
Ticker impact
Supernus entered a definitive all-stock merger agreement with Indivior, with expected close in Q4 2026 and a named post-merger structure.
Likely continued elevated volatility and upside bias while pre-market reflects deal enthusiasm, but downside risk if deal terms face regulatory or shareholder pushback.
The article discloses definitive agreement details, ownership split, cost synergies, and the post-merger ticker plan, which are direct inputs to merger-arb and probability-weighted valuation.
Indivior agreed to merge with Supernus in an all-stock transaction, including a $1 billion special cash dividend before closing.
Support from the announced $1 billion special cash dividend, with continued volatility tied to deal completion odds into Q4 2026.
The text provides concrete consideration (1.5401 SUPN shares per INDV share is not stated; instead it states SUPN stockholders receive Indivior shares, plus the $1B dividend), plus definitive agreement and expected closing quarter.
Market effects
CNS biopharma consolidation signal, potentially affecting deal expectations and valuation multiples across small-to-mid cap CNS peers.
Limited direct regional impact; transaction is US-listed and headquartered in Maryland post-close.
Moderate, as it is a bilateral deal with no stated cross-border regulatory scope in the article.
Counterpoint
Pre-market strength may fade if investors discount merger completion risk, especially given the all-stock structure and the need for approvals and shareholder votes.
Key entities
- public_companySupernus Pharmaceuticals, Inc.
Entered into a definitive agreement to merge with Indivior in an all-stock transaction, with expected close in Q4 2026.
- public_companyIndivior Pharmaceuticals, Inc.
Agreed to merge with Supernus and will receive a one-time $1 billion special cash dividend before closing.
- executiveJack Khattar
Supernus President and CEO will serve as President, CEO, and director of the combined company.
- board_memberTony Kingsley
Indivior board member to serve as board chair of the combined company.
